REGULATORY

• Sakigake Tags Granted to GSK’s Bepirovirsen, Boehringer’s Nerandomilast
  August 28, 2024

• MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
  August 26, 2024

• Astellas Pharma Employee Indicted in China
  August 23, 2024

• New LDP Study Group Seeks Budget to Bolster Immunoglobulin Production
  August 23, 2024

• BMS’ ROS1 Inhibitor, Janssen’s Bispecific Up for Review on Aug. 30
  August 20, 2024

• Kobayashi Declares Bid for LDP Race, Urges More Investment in Pharma
  August 20, 2024

• MHLW to Present Detailed Criteria for Exclusion from “Specified Clinical Trials”
  August 20, 2024

• Certain Jabs to Be Exempted from Regenerative Medicine Safety Act to Facilitate Travel Vaccination
  August 20, 2024

• Xarelto Copycats Earn Blessing, AG Might also Get on Board
  August 19, 2024

• Eisai’s ALS Therapy, Amgen’s TED Drug Up for Review on Aug. 26
  August 19, 2024

• August Generic Approval List Includes AGs for at Least 3 APIs, Acofide and More
  August 19, 2024

• Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
  August 19, 2024

• MHLW Announces Simplified New Process for Drug Delisting
  August 19, 2024

• JGA Shares Scheme of Supply Managers Council, MHLW Conferring with FTC on Feasibility
  August 9, 2024

• Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
  August 9, 2024

• Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
  August 8, 2024

• Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
  August 8, 2024

• Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
  August 8, 2024

• Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
  August 8, 2024

• AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
  August 8, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• …
• Next ›
• 最終 »